DelMar Pharmaceuticals receives IRB approval for pivotal phase 3 clinical trial of VAL-083
DelMar Pharmaceuticals announced it has received IRB approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3). DelMar's VAL-083 STAR-3 GBM trial is an adaptive design, randomized, controlled pivotal Phase 3 clinical trial in patients with GBM. June 22, 2017